Ami Patel, MD
Hematology · Salt Lake City, UTNPI 1750675948
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,185 of the $4,569 with a category attached, or 91.6%. Stemline Therapeutics Inc. accounts for 91.6% of it on its own, with 4 other manufacturers making up the rest.
Across 6 payments — averaging $761.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$4K
- Jazz Pharmaceuticals Inc.$130
- Sobi, Inc$125
- Genentech USA, Inc.$100
- E.r. Squibb & Sons, L.L.C.$29
Across 6 payments — averaging $23,015 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$138K
What the payments were for
- Consulting fees$4,18592%
- Food & beverage$3558%
- Education$291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 2 | $4,185 |
| Jazz Pharmaceuticals Inc. | 1 | $130 |
| Sobi, Inc | 1 | $125 |
| Genentech USA, Inc. | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BesremiRopeginterferon Alfa-2b-Njft | 15 | $217,500 |
| JakafiRuxolitinib Phosphate | 12 | $185,140 |
| VenclextaVenetoclax | 11 | $38,046 |
| Acyclovir | 36 | $1,155 |
| Hydroxyurea | 27 | $629 |
| Ondansetron Hcl | 14 | $148 |
Paid to pharmacies, not to this prescriber.
Other hematology in Salt Lake City
- George RodgersSalt Lake City$133K
- Deborah StephensSalt Lake City$98K
- Srinivas TantravahiSalt Lake City$81K
- Daniel ErmannSalt Lake City$74K
- Charles ParkerSalt Lake City$54K
- Jay PatelSalt Lake City$49K
- Josef PrchalSalt Lake City$48K
- Kristi SmockSalt Lake City$4K
- Margaret BaronSalt Lake City$524
- Archana AgarwalSalt Lake City$345
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.